clinical trial · NCT03238326
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase3·completed·n = 295
SchizophreniaBrexpiprazole
brief summary
To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia
started
Aug 23, 2017
primary completion
Apr 22, 2025
completion
Apr 22, 2025
last updated
Feb 4, 2026
detailed description
This is a long-term, multicenter, open-label trial designed to examine the long-term safety and tolerability of brexpiprazole in adolescent participants (ages 13-17) with a DSM-5 diagnosis of schizophrenia.
official title
A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol